Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3304-3309

  Hernández, José L ^a   Olmos, José M ^a   Romaña, Galo ^c   Llorca, Javier ^b   Martínez, Josefina ^a   Castillo, Jesús ^c   De Juan, Julia ^c   Pérez Pajares, Isabel ^c   Ruiz, Sheila ^a   González Macías, Jesús ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c Centro de Salud Camargo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TYPE 1 COLLAGEN PROPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; COLLAGEN TYPE 1; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SPINE FRACTURE; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; BONE REMODELING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; VITAMIN D;

EID: 84907200632     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1102     Document Type: Article

References (36)

1. Sood A, Arora R. Vitamin D deficiency and its correlations with increased cardiovascular incidences. Am J Ther. 2010;17: e105-e109.
2. Saliba W, Barnett O, Rennert HS, Rennert G. The risk of all-cause mortality is inversely related to serum 25(OH)D levels. J Clin Endocrinol Metab. 2012;97: 2792-2798.
3. Zheng Y, Zhu J, Zhou M, Cui L, Yao W, Liu Y. Meta-Analysis of long-Term vitamin D supplementation on overall mortality. PLoS One. 2013;8: e82109.
4. Glade MJ. Vitamin D: health panacea or false prophet? Nutrition. 2013;29: 37-41.
5. Dawson-Hughes BD, Lindsay R, Khosla S, Melton LJ III, Favus M, Baim S. Clinicians's guide to prevention and treatment of osteoporosis. 2008. Washington, DC: National Osteoporosis Foundation (www.nof.org/professionals/clinical-guidelines).
6. Karaplis AC, Chouha F, Djandji M, Sampalis JS, Hanley DA. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis. Ann Pharmacother. 2011;45: 561-568.
7. Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2013;18: 229-233.
8. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitaminDand 1,25-dihydroxyvitaminDafter rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009; 23: 295-299.
9. Ertugrul DT, Yavuz B, Kucukazman M, et al. STATIN-D Study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther. 2011; 29: 146-152.
10. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2010;2010: 957174.
11. Hernández JL, Olmos JM, Romaña G, et al. Bone mineral density in statin users: a population-based analysis from a Spanish cohort. J Bone Miner Metab. 2014;32: 184-191.
12. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 2001;86: 957-964.
13. Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012; 97: 4491-4497.
14. Hernández JL, Olmos JM, Pariente E, et al. Metabolic syndrome and bone metabolism. Menopause. 2010;17: 955-961.
15. Hernández JL, Olmos JM, González-Macías J, et al. Serum lipids and bone metabolism in Spanish men: the Camargo Cohort Study. Endocr J. 2010;57: 51-60.
16. Díez A, González-Macías J, Marín F, et al. Prediction of absolute risk of nonspinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporos Int. 2007;18: 629-639.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15: 539-555.
18. Berry EM, Gupta MM, Turner SJ, Burns RR. Variations in plasma calcium with induced changes in plasma specific gravity, total protein, and albumin. Br Med J. 1973;4: 640-643.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine, a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med. 1999;130: 461-470.
20. Riancho JA, Valero C, Hernández JL, et al. Biomechanical indices of the femoral neck estimated from the standardDXAoutput, age-And sex-related differences. J Clin Densitom. 2007;10: 39-45.
21. Genant HK, Wu CY, van Kuij C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;11: 984-996.
22. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92: 4-8.
23. Kane L, Moore K, Lütjohann D, Bikle D, Schwartz JB. Vitamin D3 effects on lipids differ in statin and non-statin-Treated humans: Superiority of free 25-OHD levels in detecting relationships. J Clin Endocrinol Metab. 2013;98: 4400-4409.
24. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-Analysis of observational studies and controlled trials. Arch Intern Med. 2004; 164: 146-152.
25. Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-Analysis. Osteoporos Int. 2005;16: 990-996.
26. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-Analysis of clinical studies. Bone 2007;40: 1581-1587.
27. Yue J, Zhang X, Dong B, Yang M. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause. 2010;17: 1071-1079.
28. Liu J, Zhu LP, Yang XL, Huang HL, Ye DQ. HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-Analysis. Bone. 2013;54: 151-156.
29. Anderson PH, Lam NN, Turner AG, et al. The pleiotropic effects of vitaminDin bone. J Steroid Biochem Mol Biol. 2013;136: 190-194.
30. Ryan JW, Reinke D, Kogawa M, et al. Novel targets of vitamin D activity in bone: action of the vitamin D receptor in osteoblasts, osteocytes and osteoclasts. Curr Drug Targets. 2013;14: 1683-1688.
31. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science.1999;286: 1946-1949.
32. Ohnaka K, Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of rho-Associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001; 287: 337-342.
33. Woo JT, Kasai S, Stern PH, Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of perfusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res. 2000;15: 650-662.
34. Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. 2013;15: 767-769.
35. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or -3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2012;17: 382-386.
36. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM. 2012;105: 487-491.